Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Perimeter completes patient enrollment for pivotal trial evaluating next-gen OCT B-Series with ImgAssist AI in breast cancer surgery

Perimeter Medical Imaging AI (TSXV:PINK; OTC:PYNKF) has announced the completion of patient enrollment in a pivotal clinical study evaluating its next-generation Perimeter B-Series OCT system, which combines proprietary...

October 3, 2024

Developments

Valerio acquires oncology biotech, Emglev

Valerio Therapeutics (Euronext Paris:ALVIO) has announced the acquisition of closely-held Emglev Therapeutics, a single-domain antibody-based therapeutic company and spinoff of Institut Curie, a leading cancer center in...

September 30, 2024

Developments

IRLAB enrolls last patient in trial of Pirepemat for Parkinson’s

IRLAB Therapeutics (STO:IRLAB-A; FRA:6IRA) has announced that it has enrolled the last patient in its ongoing Phase IIb study of Pirepemat for Parkingson’s disease. The company also reports that a reduction in falls has...

September 30, 2024

Developments

Roberto Bellini wins 2024 Bloom Burton Award

Bloom Burton has announced Roberto Bellini, former president and CEO of BELLUS Health, acquired by GlaxoSmithKline (GSK) (LSE/NYSE:GSK) in 2023, as the recipient of the 2024 Bloom Burton Award given annually to honor an...

September 27, 2024

Developments

Beyond Air and TrillaMed deploy LungFit PH into U.S. Natal Hospital Guam NICU

Beyond Air (NASDAQ:XAIR), in partnership with TrillaMed, announced that it will provide its groundbreaking LungFit PH system to the neonatal critical care unit (NICU) at U.S. Naval Hospital Guam, enabling advanced care...

September 27, 2024

Developments

Pasithea announces preliminary Phase 1 data for study of PAS-004 in advanced cancer

Pasithea Therapeutics (NASDAQ:KTTA) has announced safety, tolerability, pharmacokinetic (PK), and preliminary efficacy data from its Phase 1 clinical trial of PAS-004 in patients with MAPK pathway driven advanced solid...

September 26, 2024

Developments

NanoViricides obtains ROFR for all antiviral drug treatments from TheraCour

NanoViricides (NYSE American:NNVC) has announced that it has signed a broad memorandum of understanding agreement granting it the right of first refusal (ROFR) for all antiviral drug developments, including trojan horse...

September 26, 2024

Developments

BioRestorative’s IFATS presentation features ThermoStem’s potential to deliver a superior efficacy and tolerability profile over GLP-1 drugs

BioRestorative Therapies (NASDAQ:BTRX) presented advancements in its metabolic program, ThermoStem, targeting obesity and metabolic disorders, at the 21st Annual International Federation for Adipose Therapeutics and...

September 25, 2024

Developments

Landmark ESC guidelines update bodes well for Conavi’s Novasight Hybrid System as company nears completion of go-public transaction

The European Society of Cardiology (ESC) has elevated intracoronary imaging guidance by intravascular ultrasound (IVUS) or optical coherence tomography (OCT) to a Class 1A recommendation when performing percutaneous...

September 25, 2024

Developments

Japan’s MHLW approves Aurinia’s LUPKYNIS (voclosporin) for lupus nephritis

Aurinia Pharmaceuticals (NASDAQ:AUPH), has announced that Japan’s Ministry of Health, Labour, and Welfare (MHLW) has approved voclosporin, a second-generation calcineurin inhibitor (CNI), in combination with...

September 25, 2024

Developments

Acurx reports CDI antibiotic research results in collaboration with LUMC

Acurx Pharmaceuticals (NASDAQ:ACXP), announced results from its research, in collaboration with Leiden University Medical Center (LUMC), for its lead oral antibiotic candidate, ibezapolstat, to treat patients with C...

September 24, 2024

Developments

Zevra receives FDA approval for Miplyffa to treat NPC

Zevra Therapeutics (NASDAQ:ZVRA), has announced FDA approval for its Miplyffa oral capsules, used in combination with miglustat, for the treatment of Niemann-Pick disease C (NPC) in adult and pediatric patients aged two...

September 23, 2024

Developments

MIEC grants Aethlon full ethics approval for Hemopurifier cancer trial in India

Aethlon Medical (NASDAQ:AEMD), has announced that the Medanta Institutional Ethics Committee (MIEC) has granted full ethics approval for a safety, feasibility, and dose finding study of its Hemopurifier in cancer...

September 19, 2024

Developments

Senseonics and Ascensia receive FDA approval for world’s first CGM with 365-day sensor

Senseonics Holdings (NYSE:SENS) and closely-held Ascensia Diabetes Care herald a significant breakthrough in diabetes technology and management, announcing FDA approval of Eversense 365, the world’s first one-year...

September 18, 2024

Developments

PharmaJet and Scancell forge alliance to develop and commercialize needle-free DNA vaccine for advanced melanoma

Closely-held PharmaJet has announced a strategic partnership with Scancell Holdings (AIM:SCLP) to supply its Stratis Intramuscular (IM) Needle-free Injection System for delivery of Scancell’s advanced melanoma DNA...

September 17, 2024

Developments

Ripple and AbbVie launch strategic partnership to leverage eye care expertise and drug delivery innovation for next-gen glaucoma therapies

Closely-held Ripple Therapeutics has entered into a collaboration and option-to-lease agreement with AbbeVie (NYSE:ABBV) to develop RTC-620, a next generation, fully biodegradable, sustained-release drug delivery...

September 17, 2024

Developments

Profound’s PRO-Talk Live! 2024 spotlights the future of prostate disease care with TULSA-PRO

Profound Medical (NASDAQ:PROF; TSX:PRN) hosted its second PRO-Talk Live! educational event, by physicians for physicians, in Las Vegas this past weekend. The event featured a prestigious panel of experts, innovators...

September 16, 2024

Developments

Inspira secures additional U.S. patent approval for blood oxygenation system

Inspira Technologies (NASDAQ:IINN) has announced the approval of a second U.S. patent for VORTEX, its orbiting blood oxygenation delivery system designed to oxygenate blood without the use of fibre membranes, bringing...

September 16, 2024

Developments

Evaxion reports positive one-year Phase 2 data on personalized cancer vaccine

Evaxion Biotech (NASDAQ:EVAX) has announced positive one-year data from its Phase 2 trial of the AI-designed personalized cancer vaccine, EVX-01, a potential treatment for melanoma. The data, from a one-year interim...

September 16, 2024

Developments

Cidara’s workforce restructuring enables focus on clinical development

Cidara Therapeutics (NASDAQ:CDTX) has announced a planned workforce reduction, impacting approximately 30% of the company’s employees, enabling the company to reduce capital needs and concentrate on the clinical...

September 13, 2024

Developments

Tenon prepares to launch new joint fixation device with 30% reduction in implant width

Tenon Medical (NASDAQ:TNON) announced the limited alpha launch of its new Catamaran SE SI Joint Fusion System in early Q4. The company aims to gather initial user feedback from a select group of physicians to support a...

September 13, 2024

Developments

Aura announces positive Phase 2 EOS results evaluating bel-sar for CM

Aura Biosciences (NASDAQ:AURA) has announced positive Phase 2 end-of-study (EOS) results evaluating the safety, tolerability, and efficacy of bel-sar (AU-011) for the first-line treatment of early-stage choroidal...

September 12, 2024

Perimeter completes patient enrollment for pivotal trial evaluating next-gen OCT B-Series with ImgAssist AI in breast cancer surgery

Valerio acquires oncology biotech, Emglev

IRLAB enrolls last patient in trial of Pirepemat for Parkinson’s

Roberto Bellini wins 2024 Bloom Burton Award

Beyond Air and TrillaMed deploy LungFit PH into U.S. Natal Hospital Guam NICU

Pasithea announces preliminary Phase 1 data for study of PAS-004 in advanced cancer

NanoViricides obtains ROFR for all antiviral drug treatments from TheraCour

BioRestorative’s IFATS presentation features ThermoStem’s potential to deliver a superior efficacy and tolerability profile over GLP-1 drugs

Landmark ESC guidelines update bodes well for Conavi’s Novasight Hybrid System as company nears completion of go-public transaction

Japan’s MHLW approves Aurinia’s LUPKYNIS (voclosporin) for lupus nephritis

Acurx reports CDI antibiotic research results in collaboration with LUMC

Zevra receives FDA approval for Miplyffa to treat NPC

MIEC grants Aethlon full ethics approval for Hemopurifier cancer trial in India

Senseonics and Ascensia receive FDA approval for world’s first CGM with 365-day sensor

PharmaJet and Scancell forge alliance to develop and commercialize needle-free DNA vaccine for advanced melanoma

Ripple and AbbVie launch strategic partnership to leverage eye care expertise and drug delivery innovation for next-gen glaucoma therapies

Profound’s PRO-Talk Live! 2024 spotlights the future of prostate disease care with TULSA-PRO

Inspira secures additional U.S. patent approval for blood oxygenation system

Evaxion reports positive one-year Phase 2 data on personalized cancer vaccine

Cidara’s workforce restructuring enables focus on clinical development

Tenon prepares to launch new joint fixation device with 30% reduction in implant width

Aura announces positive Phase 2 EOS results evaluating bel-sar for CM

General

More